Table 1.
Patient characteristics
| Median age, years (range) | 55 | (13–74) |
| Median number of previous chemotherapy regimens (range) |
2 | (0–8) |
| No. of patients | (%) | |
| Patient sex | ||
| Male/female | 108/73 | 60/40 |
| Source of stem cells | ||
| PB | 96 | 53 |
| BM | 85 | 47 |
| Donor type | ||
| Matched related | 92 | 51 |
| Matched unrelated | 89 | 49 |
| Donor type/source of stem cells | ||
| Matched related/PB | 77 | 42 |
| Matched related/BM | 15 | 8 |
| Matched unrelated/PB | 19 | 10 |
| Matched unrelated/BM | 70 | 39 |
| Disease status at transplantation | ||
| CR | 52 | 29 |
| Active disease without circulating blasts | 71 | 39 |
| Active disease with circulating blasts | 58 | 32 |
| Karyotype risk group | ||
| High | 77 | 42 |
| Intermediate | 95 | 52 |
| Low | 5 | 3 |
| Undetermined | 4 | 2 |
| Conditioning regimen | ||
| Fludarabine/melpahalan±ATGa | 164 | 91 |
| Fludarabine/melpahalan/mylotarg±ATGa | 17 | 9 |
| GVHD prophylaxis | ||
| Tacrolimus/MTX | 168 | 93 |
| Tacrolimus/MTX/pentostatina | 10 | 5 |
| Tacrolimus±other | 2 | 1 |
| CYA/steroids | 1 | 0.6 |
| Response day +30 after transplantationb | ||
| CR | 159 | 95 |
| Other | 8 | 5 |
Abbreviations: ATG = antithymocyte globulin; PB = peripheral blood.
a
ATG and pentostatin were added only in recipients of a graft from a matched unrelated donor.
b
Evaluated in 167/181 patients who were alive and engrafted on post transplant day +30